Total
0
Shares
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald
CEO, James Graham
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) has reported further findings from its fee-for-service collaboration between CSIRO and the Doherty Institute
  • The latest round of results are from ongoing testing of its anti-infective drug R237 against SARS-CoV-2, the virus that causes COVID-19
  • According to RCE, the results confirm and extend the findings from testing in February, which found R327 to be 99.9 per cent effective against SARS-CoV-2 at higher doses
  • On the basis of these findings, Recce has been issued a qualified recommendation to proceed to stage two of the programme
  • Recce Pharmaceuticals shares closed the day in the grey to trade at $1.13

Recce Pharmaceuticals (RCE) has reported further findings from its fee-for-service collaboration between the CSIRO and the Doherty Institute.

The company's synthetic anti-infective drug R327 is being tested against SARS-CoV-2, the virus that causes COVID-19, in further stage 1B studies conducted by the parties.

According to RCE, results from this particular stage confirmed and extended the findings from the previous report and allowed the half maximal inhibitory concentration (IC50) of 2,046ppm and cytotoxicity (CC50) of 5,108ppm of R327 to be determined.

Broadly, Recce affirms R327 has been shown to be effective and not highly toxic to a small window of concentrations in preliminary testing and has therefore received a qualified recommendation to proceed to stage two of the programme.

The next round of testing is set to include further testing in normal human bronchial epithelial cells grown at the air-liquid interface, with results expected towards the end of the year.

The pharmaceutical player advised further testing will need to be completed in order to determine whether R327 will show an inhibitory effect against the SARS-CoV-2 virus without associated toxicity.

Non-Executive Chairman Dr John Prendergast described the results as encouraging.

"These results continue to reinforce our confidence in the potential of R327 against SARS-CoV-2 as another line of defence in the arsenal against COVID-19," he said.

Recce Pharmaceuticals shares closed the day in the grey to trade at $1.13.

RCE by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) brings ColoSTAT trial to Queensland

" Proteomics International Laboratories (ASX:PIQ) to collaborate for world’s first endometriosis test

Proteomics International Laboratories (PIQ) has penned a research agreement to develop a non-invasive test for endometriosis.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) secures two deals to integrate its diagnostic test

ResApp Health (RAP) has secured two new agreements for its smartphone-based acute respiratory diagnostic test.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" FDA requests further clarification from Paradigm Biopharmaceuticals (ASX:PAR)

The US Food and Drug Administration has requested further clarification from Paradigm Biopharmaceuticals (PAR) for its Investigational New Drug (IND) application.
Patrys (ASX:PAB) - CEO and Managing Director, Dr James Campbell - The Market Herald

" Patrys’ (ASX:PAB) clinical trials pushed back

Patrys’ (PAB) planned PAT-DX1 clinical trial will be postponed for up to six months due to global manufacturing and supply chain delays.